Newron Pharmaceuticals S.p.A. Stock CBOE
Stocks
0QOI
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
CBOE
11:20:00 2026-09-29 EDT
|
5-day change | 1st Jan Change | ||
| 8.240 CHF | +6.32% |
|
-32.02% | -67.64% |
| Market Cap | 183M 207M 173M 157M 294M 19.87B 297M 2.07B 799M 10.15B 777M 761M 32.65B | P/E 2026 * |
-6.59x | P/E 2027 * | 246x |
|---|---|---|---|---|---|
| Enterprise Value | 197M 223M 186M 169M 317M 21.41B 320M 2.24B 861M 10.93B 838M 820M 35.19B | EV / Sales 2026 * |
23.2x | EV / Sales 2027 * | 5.04x |
| Free-Float |
87.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| NWRN | Delayed | |
Börse Stuttgart
| NP5 | Delayed | |
|
Tradegate
| NP5 | Real-time | |
|
Xetra
| NP5 | Delayed | |
|
CBOE
| 0QOI | Real-time | |
|
Boerse Muenchen
| NP5 | Real-time | |
|
London S.E.
| 0QOI | Delayed | |
|
Deutsche Boerse AG
| NP5 | Delayed |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 week | -25.09% | ||
| Current month | -33.33% | ||
| 1 month | -33.01% | ||
| 3 months | -35.02% | ||
| 6 months | -43.60% | ||
| Current year | -65.59% |
| 1 week | 7.62 |  | 11.5 |
| 1 month | 7.62 | | 12.64 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 2012-05-14 |
Roberto Galli
DFI | Director of Finance/CFO | - | 2011-12-31 |
Filippo Moriggia
COO | Chief Operating Officer | - | 2021-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 2012-05-14 |
Gillian Dines
BRD | Director/Board Member | - | 2023-03-31 |
Margarita Chavez
BRD | Director/Board Member | - | 2024-04-16 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.32% | -32.02% | - | - | 195M | |
| -0.03% | +6.41% | +11.83% | +38.36% | 49.06B | |
| -0.73% | -0.41% | +48.84% | +36.72% | 44.6B | |
| +1.36% | +6.03% | +343.85% | +638.73% | 43.24B | |
| -0.47% | -0.76% | +9.75% | +103.07% | 41.73B | |
| +0.34% | -1.38% | +5.53% | +47.36% | 29.93B | |
| +1.00% | -1.28% | +24.23% | +156.93% | 17.19B | |
| -2.94% | +6.98% | +5.10% | - | 15.35B | |
| -3.20% | -2.38% | +25.00% | +43.67% | 15.54B | |
| -0.86% | -4.00% | - | - | 15.11B | |
| Average | -0.57% | +1.76% | +59.27% | +152.12% | 30.19B | |
| Weighted average by Cap. | -0.26% | +2.17% | +74.36% | +166.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.49M 9.62M 8.03M 7.28M 13.65M 923M 13.79M 96.34M 37.13M 471M 36.11M 35.33M 1.52B | 39.86M 45.17M 37.72M 34.21M 64.13M 4.33B 64.76M 452M 174M 2.21B 170M 166M 7.12B |
| Net income | -29.99M -33.99M -28.38M -25.74M -48.25M -3.26B -48.73M -340M -131M -1.67B -128M -125M -5.36B | -1.96M -2.22M -1.85M -1.68M -3.15M -213M -3.18M -22.2M -8.56M -109M -8.32M -8.14M -349M |
| Net Debt | 14.21M 16.1M 13.44M 12.19M 22.86M 1.55B 23.09M 161M 62.16M 789M 60.46M 59.15M 2.54B | 18.13M 20.55M 17.16M 15.56M 29.17M 1.97B 29.46M 206M 79.32M 1.01B 77.15M 75.47M 3.24B |
| Date | Price | Change |
|---|---|---|
| 26-09-29 | CHF 8.240 | +6.32% |
| 26-09-28 | CHF 7.750 | -27.02% |
| 26-09-25 | CHF 10.62 | -1.76% |
| 26-09-24 | CHF 10.81 | -4.00% |
| 26-09-23 | CHF 11.26 | +2.36% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
- 0QOI Stock
Select your edition
All financial news and data tailored to specific country editions
